Figure 6.

CD39⁺ HBVs-CAR-T cells and CD39⁺ PTL-HBVs-CAR-T cells exerted potent antitumor activity in the PDX model

(A and B) HCC organoids at 5 × 10⁶ cells were inoculated s.c. into NSG mice. Fifteen days later, various CAR-T cells were infused via tail injection, and GP120-CAR-T cells (NC-CAR-T cells) served as NC. All of the tumors were measured every 5 days (n = 5). (C–E) At day 40, tumors were resected from the mice, followed by digestion and FACS analysis. The percentage of infiltrating CAR-T cells in tumor (C and D) and the percentages of IFN-γ⁺ cells in tumor-infiltrating CAR-T cells (E) were shown among different groups. ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.0005 (1-way ANOVA). All data are means ± SEMs.